When should sacubitril‑valsartan (Entresto) be discontinued in a patient with heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

When to Discontinue Sacubitril/Valsartan

Sacubitril/valsartan should rarely be permanently discontinued in heart failure patients, as discontinuation is associated with significantly increased mortality and clinical deterioration. 1, 2, 3

Absolute Indications for Immediate Discontinuation

Stop sacubitril/valsartan immediately and permanently if:

  • Angioedema occurs - Do not re-administer under any circumstances. Provide appropriate therapy including subcutaneous epinephrine 1:1000 (0.3-0.5 mL) if laryngeal involvement 1
  • Pregnancy is detected - Switch to alternative therapy unless the drug is considered lifesaving for the mother and no appropriate alternative exists 1
  • Severe hypersensitivity reaction to either sacubitril or valsartan components 1

Temporary Discontinuation or Dose Reduction Scenarios

For symptomatic hypotension:

  • First, adjust diuretics and other vasodilators (nitrates, calcium channel blockers) 1
  • Correct volume depletion if present
  • If hypotension persists despite these measures, reduce the dose by 50% rather than discontinuing 1
  • Permanent discontinuation is usually not required 1

For significant renal dysfunction:

  • If serum creatinine doubles or eGFR drops significantly, down-titrate the dose rather than stop 1
  • Monitor closely and adjust diuretics
  • Consider temporary interruption only if acute kidney injury develops, with plan to restart when stable 4

For hyperkalemia:

  • If potassium >5.5 mmol/L: reduce dose by 50% 5
  • If potassium >6.0 mmol/L: temporarily stop and seek specialist advice, but plan to restart with potassium management 5
  • Consider potassium binders (patiromer, zirconium cyclosilicate) to enable continuation 4

Critical Evidence on Discontinuation Outcomes

The evidence strongly argues against discontinuation. Patients who discontinued sacubitril/valsartan showed:

  • 13-fold increased cardiovascular mortality (HR 13.22,95% CI 6.71-15.73) 3
  • 13.5-fold increased all-cause mortality (HR 13.51,95% CI 3.22-56.13) 3
  • Worsening NYHA class, declining LVEF, and increased end-diastolic volume even when switched back to ACE inhibitors or ARBs 2

Management Algorithm for Adverse Events

Instead of discontinuing, follow this sequence:

  1. For hypotension (most common reason for discontinuation):

    • Separate timing of sacubitril/valsartan from other BP-lowering medications 6
    • Reduce or stop non-essential vasodilators first
    • Down-titrate diuretics if no congestion present
    • Reduce sacubitril/valsartan dose only as last resort
    • Note: Asymptomatic low BP does not require intervention 5, 7
  2. For worsening heart failure symptoms:

    • Increase diuretics first 5
    • Only temporarily reduce sacubitril/valsartan dose if diuretic adjustment fails
    • Seek specialist advice before stopping 5
  3. For renal dysfunction:

    • Up to 30% increase in creatinine is acceptable and does not require dose change 6
    • Adjust diuretics to optimize volume status
    • Monitor closely but continue therapy if possible 4

Special Populations Requiring Caution

Higher discontinuation risk in patients with:

  • ATTR cardiac amyloidosis (76.5% discontinuation rate, primarily due to hypotension) 8
  • Advanced NYHA Class IV heart failure (18% unable to tolerate even during run-in, 29% discontinued during trial) 9
  • Baseline SBP <110 mmHg 7, 10
  • Albumin <3.5 g/dL or BMI <18.5 kg/m² 11

These patients require more intensive monitoring but should still attempt therapy given the mortality benefit.

Key Pitfalls to Avoid

  • Do not stop abruptly without attempting dose reduction first - permanent discontinuation is rarely necessary 1
  • Do not discontinue for asymptomatic hypotension or mild creatinine elevation - these often stabilize with supportive measures 7
  • Do not assume ACE inhibitors/ARBs are equivalent alternatives - switching back results in worse outcomes 2
  • Do not delay restarting after temporary interruption - the longer the delay, the worse the outcomes 3

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.